ArticleEuropean journal of nuclear medicine and molecular imaging2025
Comparison of PSMA immunohistochemistry scoring systems to parametric [
Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Relationship between [European journal of nuclear medicine and molecular imaging · 2026Trial
- Response to: 'Methodological concerns on prostate-specific membrane antigen (PSMA) immunohistochemistry for predicting PSMA-PET avidity'.BJU international · 2026Article
- The value of [Quantitative imaging in medicine and surgery · 2026Article
- Transcriptional network analysis of PTEN-protein-deficient prostate tumors reveals robust stromal reprogramming and signs of senescent paracrine communication.Molecular oncology · 2026Article
- The Caspase-1-EGR4 axis regulates macrophage repolarization in acute myeloid leukemia cells.Scientific reports · 2026Article
- Interreader agreement of intraprostatic prostate cancer detection, local extension and staging using [EJNMMI research · 2026Article
- AI-driven precision diagnosis and treatment of prostate cancer: a narrative review.Frontiers in oncology · 2026Review
- A novel nomogram based on DLL3 and PD-L1 for predicting the prognosis of patients with small cell lung cancer.BMC cancer · 2025Article
- Cyclin D1 expression predicts mismatch repair deficiency and correlates significantly with overall survival and recurrence free survival in endometrial carcinoma.Journal of molecular histology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
purposeQuantification of PSMA expression via PSMA PET is well-established, however quantification of PSMA via immunohistochemistry (IHC) is not standardized. Our aim was to determine the most optimal PSMA IHC scoring system to quantify PSMA expression with PSMA PET as reference standard.
methodsPrimary intermediate- and high-risk prostate cancer patients received an [
resultsFifty tumors in 46 patients were analysed. H-score had the best correlation with SUV
conclusionH-score had the best correlation with PSMA PET quantification and an acceptable interreader agreement. Therefore, we deem H-score the most optimal PSMA IHC scoring system.
Indexed as
Identifiers
39269656What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.